Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: johnsto1 who wrote (28761)	6/30/2000 7:47:17 AM
From: kendall harmon	Respond to of 57584

GNSL had news last night after the close <<ANN ARBOR, Mich., June 29 /PRNewswire/ -- Genomic Solutions Inc. (Nasdaq: GNSL - news), one of the world's leading suppliers of automated solutions for genomics and proteomics, today announced the company will install two complete proteomics systems for new facilities at the prestigious John Innes Centre (JIC) and the Institute of Food Research (IFR), both located in Norwich, Norfolk, UK. The facilities are scheduled to open September 29, 2000. These installations bring the total number of Genomic Solutions automated proteomic systems in Europe to seven, with two in Germany and five in the UK. Merck Sharpe and Dohme, a major pharmaceutical company, and the University of Aberdeen are among customers using the Investigator(TM) Proteomic System. ``We chose Genomic Solutions to provide the proteomics instrumentation because we assessed other suppliers and Genomic Solutions was the company that could provide the full specification we wanted, when we wanted it,'' said Dr. Nick Walton, Senior Research Scientist, IFR, speaking on behalf of both Institutes. ``It is also very important to us to have systems that both institutes can use to interchange data with collaborators both on- and off- site. In addition, we felt confident that Genomic Solutions would provide good, on-going application and service support for both facilities,'' he noted. Genomic Solutions Inc. designs, develops, manufactures, markets and sells instruments, software, consumables and services used to determine the activity level of genes and to isolate, identify and characterize proteins. The company's products and systems enable researchers to perform complex, high volume experiments at a lower cost and in less time than traditional techniques. As a result, Genomic Solutions products and systems facilitate more rapid and less expensive drug discovery. Genomic Solutions markets products through its corporate headquarters in Ann Arbor, Michigan USA, as well as offices in the United Kingdom and Japan. Remaining worldwide distribution is provided by PerkinElmer Life Sciences through a strategic alliance with Genomic Solutions. The two companies also cooperate to sell co-branded products and collaborate to leverage their intellectual property and technologies. JIC is a leading international center for research and training in plant and microbial science. It generates and disseminates new knowledge, understanding and valuable intellectual property in selected plants and microbes include plant pathogens. IFR is a premier international center for independent, multi-disciplinary research in food safety, diet and health, food quality and consumer sciences, including fundamental investigations of nutrient-gene interactions, the physiology and molecular genetics of food pathogens and the physicochemical properties of food materials. The proteomics facilities will enable both institutes to make full use of the data rapidly emerging from a wide range of genome-sequencing projects to understand the factors which control and influence gene expression at the protein level. Statements in this press release that are not strictly historical are ``forward-looking'' statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve a high degree of risk and uncertainty that exist in the Company's operations and business environment. Such statements are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could affect actual events or results include risks associated with performance under the Company's agreements with third parties, research and development progress, competitive products and the strength of the Company's patent portfolio. These factors and others are more fully described under ``Risk Factors'' in the Final Prospectus included in the Company's Registration Statement on Form S-1 (File No. 333-30246) as filed with the Securities and Exchange Commission and declared effective by the SEC on May 4, 2000. For more information, contact us at info@genomicsolutions.com or visit our Website, www.genomicsolutions.com .>> biz.yahoo.com